Bortezomib therapy‐related lung disease in J apanese patients with multiple myeloma: Incidence, mortality and clinical characterization-Reference-Cited by-同舟云学术

Bortezomib therapy‐related lung disease in J apanese patients with multiple myeloma: Incidence, mortality and clinical characterization

Published:2014-01-21 Issue:2 Volume:105 Page:195-201
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Yoshizawa Kazutake¹,Mukai Harumi Y.¹,Miyazawa Michiko²,Miyao Makiko²,Ogawa Yoshimasa²,Ohyashiki Kazuma³,Katoh Takao⁴,Kusumoto Masahiko⁵,Gemma Akihiko⁶,Sakai Fumikazu⁷,Sugiyama Yukihiko⁸,Hatake Kiyohiko⁹,Fukuda Yuh¹⁰,Kudoh Shoji¹¹

Affiliation:

1. Division of Medical Affairs Janssen Pharmaceutical K.K.Tokyo Japan

2. Division of Research and Development Janssen Pharmaceutical K.K. Tokyo Japan

3. First Department of Internal Medicine Tokyo Medical University Tokyo Japan

4. Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine Department of Internal Medicine Nippon Medical School Tokyo Japan

5. Division of Diagnostic Radiology National Cancer Center Hospital Tokyo Japan

6. Division of Pulmonary Medicine, Infectious Disease and Oncology Department of Internal Medicine Nippon Medical School Tokyo Japan

7. Department of Radiology Saitama Medical University International Medical Center Hidaka‐shi Japan

8. Division of Pulmonary Medicine Department of Medicine Jichi Medical University Shimotsuke‐shi Japan

9. Department of Hematology Oncology Cancer Institute Hospital TokyoJapan

10. Department of Analytic Human Pathology Nippon Medical School Tokyo Japan

11. Double‐Barred Cross Hospital Japan Anti‐Tuberculosis Association Tokyo Japan

Funder

Janssen Pharmaceutical K.K.

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12335

Reference25 articles.

1. Bortezomib in the Treatment of Cancer

2. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

3. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma

4. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

5. Lung Injury Associated with Bortezomib Therapy in Relapsed/Refractory Multiple Myeloma in Japan: A Questionnaire-Based Report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3;Japanese Journal of Clinical Oncology;2024-05-24

2. Proteasome Inhibitor (Bortezomib);Analysis File of Drug-Induced Lung Injury;2024

3. Analysis of medical malpractice liability disputes related to novel antineoplastic drugs and research on risk prevention and control strategies;PLOS ONE;2023-06-05

4. Systemic Capillary Leak Syndrome (SCLS) Presentation in Patients Receiving Anti-cancer Treatments;Cureus;2023-04-30

5. Bortezomib-induced diffuse alveolar hemorrhage in a patient with plasma cell leukemia;Respiratory Medicine Case Reports;2020